— Know what they know.
Not Investment Advice

PCRX NASDAQ

Pacira BioSciences, Inc.
1W: +0.4% 1M: -5.2% 3M: -1.5% YTD: +3.1% 1Y: -0.2% 3Y: -18.8% 5Y: -56.4%
$25.21
+0.20 (+0.80%)
 
Weekly Expected Move ±4.5%
$23 $24 $25 $26 $27
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 50 · $991.6M mcap · 38M float · 1.45% daily turnover · Short 55% of daily vol
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$991.6M
52W Range18.8-27.66
Volume469,793
Avg Volume545,387
Beta0.27
Dividend—
Analyst Ratings
15 Buy 17 Hold 4 Sell
Consensus Hold
Company Info
CEOFrank D. Lee
Employees827
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2011-02-03
Websitepacira.com
2000 Sierra Point Parkway
Brisbane, CA 94005
US
813 553 6680
About Pacira BioSciences, Inc.

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

Recent Insider Trades

NameTypeSharesPriceDate
SLONIN JONATHAN S-Sale 3,040 $23.23 2026-08-17
RIKER LAUREN S-Sale 6,115 $23.50 2026-06-11
Hirawat Samit A-Award 10,891 $23.42 2026-06-10
Hirawat Samit A-Award 6,405 — 2026-06-10
CHRISTIE CHRISTOPHER A-Award 6,405 — 2026-06-10

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms